CCM
NAGE

Coe Capital Management’s Niagen Bioscience NAGE Stock Holding History

Coe Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-164,994
Closed -$683K – 258
2016
Q2 		$683K Buy
+164,994
New +$781K 0.24% 124

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Silver Capital Management New York $5.22M AUM 15.18% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Coe Capital Management's NAGE Position: Q3 2016 in Review

Coe Capital Management sold out of Niagen Bioscience (NAGE) in Q3 2016, closing a stake of 164,994 shares — an estimated $683K sold.

Coe Capital Management first reported a position in NAGE in Q2 2016 and held it in 1 quarter. The position peaked at $683K in Q2 2016. 50 funds tracked by Wall St. Rank hold NAGE as of Q3 2016.

  • Coe Capital Management reported no remaining Niagen Bioscience position as of Q3 2016 after selling out during the quarter.
  • Coe Capital Management sold 164,994 Niagen Bioscience shares in Q3 2016, an estimated $683K.
  • Coe Capital Management first reported a position in Niagen Bioscience in Q2 2016 and held it in 1 quarter.
  • Coe Capital Management's Niagen Bioscience position peaked at $683K in Q2 2016.
  • 50 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2016.

Based on Coe Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.